• Molecular NameAtovaquone
  • SynonymNA
  • Weight366.844
  • Drugbank_IDDB01117
  • ACS_NO95233-18-4
  • Show 2D model
  • LogP (experiment)5.251
  • LogP (predicted, AB/LogP v2.0)4.58
  • pkaN/A
  • LogD (pH=7, predicted)2.24
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-5.49
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds2
  • TPSA54.37
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA chemical compound that belongs to the class of naphthalenes. Atovaquone is a hydroxy-1,4-naphthoquinone, an analog of ubiquinone, with antipneumocystic activity.
  • Absorption_valueN/A
  • Absorption (description)Atovaquone is rapidly but poorly absorbed after oral administration
  • Caco_2N/A
  • Bioavailability23.0
  • Protein binding99.9
  • Volume of distribution (VD)0.6 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThere is no evidence that atovaquone is metabolised in the body. It may undergo enterohepatic recycling.
  • Half life60~70 h
  • ExcretionThe drug is excreted almost entirely in faeces (94% of an administered dose over 21 days) as the unchanged drug, with little present in urine.
  • Urinary ExcretionN/A
  • Clerance0.15 ml/min/kg; also, reported as 1.56 L/h.
  • ToxicityIt is safe to give doses of up to 3000 mg daily.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A